- Home
- LAC vs EYPT Comparison
LAC vs EYPT Comparison
Compare LAC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAC
- EYPT
- Stock Information
- Founded
- LAC 2023
- EYPT 1987
- Country
- LAC Canada
- EYPT United States
- Employees
- LAC N/A
- EYPT N/A
- Industry
- LAC Metal Mining
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- LAC Basic Materials
- EYPT Industrials
- Exchange
- LAC Nasdaq
- EYPT Nasdaq
- Market Cap
- LAC 553.8M
- EYPT 579.4M
- IPO Year
- LAC N/A
- EYPT 2005
- Fundamental
- Price
- LAC $2.59
- EYPT $9.82
- Analyst Decision
- LAC Hold
- EYPT Strong Buy
- Analyst Count
- LAC 5
- EYPT 8
- Target Price
- LAC $3.75
- EYPT $24.75
- AVG Volume (30 Days)
- LAC 10.5M
- EYPT 628.3K
- Earning Date
- LAC 08-12-2025
- EYPT 08-06-2025
- Dividend Yield
- LAC N/A
- EYPT N/A
- EPS Growth
- LAC N/A
- EYPT N/A
- EPS
- LAC N/A
- EYPT N/A
- Revenue
- LAC N/A
- EYPT $56,042,000.00
- Revenue This Year
- LAC N/A
- EYPT N/A
- Revenue Next Year
- LAC N/A
- EYPT N/A
- P/E Ratio
- LAC N/A
- EYPT N/A
- Revenue Growth
- LAC N/A
- EYPT 12.04
- 52 Week Low
- LAC $2.02
- EYPT $3.91
- 52 Week High
- LAC $5.20
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- LAC 39.65
- EYPT 49.58
- Support Level
- LAC $3.11
- EYPT $9.77
- Resistance Level
- LAC $3.44
- EYPT $10.41
- Average True Range (ATR)
- LAC 0.22
- EYPT 0.53
- MACD
- LAC -0.07
- EYPT -0.16
- Stochastic Oscillator
- LAC 8.85
- EYPT 8.70
About LAC Lithium Americas Corp.
Lithium Americas is a pure-play lithium producer. The firm owns 62% of one resource, Thacker Pass, that is located in northwest Nevada, with automaker General Motors owning the remaining 38%. Thacker Pass recently began construction and is expected to begin production in the late 2020s. Thacker Pass is one of the largest known lithium resources in the world. The project would be the first clay-based asset to enter production, and we estimate it will be in bottom half of the global cost curve. Management plans to develop Thacker Pass into a fully integrated lithium production site, with downstream refining capabilities on site, and will sell into the lithium chemical market.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.